ESMO 2019

REVIEW UroToday

Viewing 1-20 of 138 articles

ESMO 2019: Invited Discussant: The CARD Trial - Cabazitaxel as Third Line Therapy in Metastatic Castration-Resistant Prostate Cancer

ESMO 2019: Invited Discussant: How Do the Results of IMvigor130 Change Things in Bladder Cancer?

ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Systemic Treatment: The Role of Chemotherapy and Androgen Receptor Targeted Therapy

ESMO 2019: Invited Discussant - Phase 3 PROfound Study for Metastatic Castration-resistant Prostate Cancer (LBA12)

ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial

ESMO 2019: The CARD Trial, A Randomized, Open-Label Study of Cabazitaxel vs Abiraterone or Enzalutamide in mCRPC, Discussion

ESMO 2019: Invited Discussant: IMvigor130: Phase III Study of Atezolizumab with or without Platinum-Based Chemotherapy in Previously Untreated Metastatic Urothelial Carcinoma

ESMO 2019: EV-103 Enfortumab Vedotin plus Pembrolizumab for Urothelial Carcinoma

ESMO 2019: Invited Discussant: Testicular and Kidney Cancer (913PD - APACHE (Testicular), 914PD (Testicular) , and 915PD (RCC))

ESMO 2019: Prognostic Factors in Metastatic Seminomatous Germ Cell Tumors and Elevated HCG – a Study of the G3

ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Advances in Pelvic Nodal Radiotherapy

ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Is there a Role for Radical Surgery?

ESMO 2019: Results from a Global Patient Survey: Diagnosis, Management, and Burden of Renal Cell Carcinomas - A Medical Oncologist’s Perspective

ESMO 2019: Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma

ESMO 2019: Invited Discussant: Results of the IMVigor130 Study of Atezoluzumab as Monotherapy, or in Combination with Platinum Chemotherapy for Patients with Advanced or Metastatic Urothelial Carcinoma

ESMO 2019: APACHE: An Open Label, Randomized, Phase II Study of Durvalumab Alone or in Combination with Tremelimumab, in Patients with Refractory Germ Cell Tumors: Results from the Expanded Combination Therapy Cohort

ESMO 2019: Immune Therapy in Combination with Targeted Therapy

ESMO 2019: Efficacy and Safety of Nivolumab in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer in CheckMate 9KD

ESMO 2019: Invited Discussant: (911PD and 912PD) New Anti-Angiogenic Treatments for Kidney Cancer

ESMO 2019: Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: A Subgroup Analysis on Efficacy and Biomarkers from the Phase 3 JAVELIN Renal 101 Trial of First-Line Avelumab plus Axitinib versus Sunitinib

1
2
3
4
5
6
7